There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Surgery ...

In this photo illustration, the Range Resources company logo is seen displayed ... More on a smartphone screen. (Photo ...

Capital Group Private Client Services Inc. reduced its Regeneron holdings by 17.6% in Q4, offloading 19,565 shares, but still ...

Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD Injection 8 mg. The sBLA seeks ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $150 from $170 and keeps a Hold rating on the shares. The ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Cerity Partners gave Regeneron a small but mighty vote of confidence, upping their stake by 3.3% in the fourth quarter. They ...